Search Result

Results for "

Lipid-lowering

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Akt (1) AMPK (2) Antibiotic (2) Apical Sodium-Dependent Bile Acid Transporter (1) Apolipoprotein (1) Apoptosis (5) ATP Citrate Lyase (1) Autophagy (5) Bacterial (2) Biochemical Assay Reagents (2) Carnitine Palmitoyltransferase (CPT) (1) Cytochrome P450 (6) Dipeptidyl Peptidase (2) Drug Derivative (3) Drug Metabolite (5) Endogenous Metabolite (10) Epoxide Hydrolase (2) ERK (1) Estrogen Receptor/ERR (1) Farnesyl Transferase (3) Fatty Acid Synthase (FASN) (2) Ferroptosis (3) FGFR (1) Free Fatty Acid Receptor (1) FXR (3) G protein-coupled Bile Acid Receptor 1 (1) GLP Receptor (1) Glycosidase (2) HCV (3) HMG-CoA Reductase (HMGCR) (7) Hydroxycarboxylic Acid Receptor (HCAR) (1) Influenza Virus (2) Interleukin Related (1) Isotope-Labeled Compounds (4) JAK (2) Keap1-Nrf2 (3) LDLR (10) Microsomal Triglyceride Transfer Protein (MTP) (1) Mitochondrial Metabolism (1) MMP (1) Monoamine Oxidase (1) mTOR (1) NF-κB (2) NO Synthase (2) NOD-like Receptor (NLR) (1) Nuclear Hormone Receptor 4A/NR4A (1) PCSK9 (6) Phosphatase (1) PI3K (1) Potassium Channel (2) PPAR (12) Prostaglandin Receptor (1) Pyroptosis (1) RAR/RXR (1) Reactive Oxygen Species (ROS) (1) Reference Standards (14) ROR (1) SARS-CoV (2) Thyroid Hormone Receptor (1) β-glucuronidase (1)
By Research Areas:	Cancer (24) Cardiovascular Disease (32) Endocrinology (5) Infection (10) Inflammation/Immunology (18) Metabolic Disease (59) Neurological Disease (9)

By Targets:

Acyltransferase (1)

Akt (1)

AMPK (2)

Antibiotic (2)

Apical Sodium-Dependent Bile Acid Transporter (1)

Apolipoprotein (1)

Apoptosis (5)

ATP Citrate Lyase (1)

Autophagy (5)

Bacterial (2)

Biochemical Assay Reagents (2)

Carnitine Palmitoyltransferase (CPT) (1)

Cytochrome P450 (6)

Dipeptidyl Peptidase (2)

Drug Derivative (3)

Drug Metabolite (5)

Endogenous Metabolite (10)

Epoxide Hydrolase (2)

ERK (1)

Estrogen Receptor/ERR (1)

Farnesyl Transferase (3)

Fatty Acid Synthase (FASN) (2)

Ferroptosis (3)

FGFR (1)

Free Fatty Acid Receptor (1)

FXR (3)

G protein-coupled Bile Acid Receptor 1 (1)

GLP Receptor (1)

Glycosidase (2)

HCV (3)

HMG-CoA Reductase (HMGCR) (7)

Hydroxycarboxylic Acid Receptor (HCAR) (1)

Influenza Virus (2)

Interleukin Related (1)

Isotope-Labeled Compounds (4)

JAK (2)

Keap1-Nrf2 (3)

LDLR (10)

Microsomal Triglyceride Transfer Protein (MTP) (1)

Mitochondrial Metabolism (1)

MMP (1)

Monoamine Oxidase (1)

mTOR (1)

NF-κB (2)

NO Synthase (2)

NOD-like Receptor (NLR) (1)

Nuclear Hormone Receptor 4A/NR4A (1)

PCSK9 (6)

Phosphatase (1)

PI3K (1)

Potassium Channel (2)

PPAR (12)

Prostaglandin Receptor (1)

Pyroptosis (1)

RAR/RXR (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (14)

ROR (1)

SARS-CoV (2)

Thyroid Hormone Receptor (1)

β-glucuronidase (1)

By Research Areas:

Cancer (24)

Cardiovascular Disease (32)

Endocrinology (5)

Infection (10)

Inflammation/Immunology (18)

Metabolic Disease (59)

Neurological Disease (9)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W001171

3-Hydroxyanthranilic acid 1 Publications Verification	Endogenous Metabolite	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology Cancer
3-Hydroxyanthranilic acid is a tryptophan metabolite in the kynurenine pathway.3-hydroxyanthranilic acid has anti-inflammatory, neuroprotective, and lipid-lowering effects. 3-hydroxyanthranilic acid can be used for researches of cardiovascular diseases, tumors, and metabolic diseases .

HY-N6653

Lentinan Maximum Cited Publications 8 Publications Verification	JAK Keap1-Nrf2 Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
Lentinan is an orally active biocompatible multifunctional polysaccharide with biological activities such as anti-inflammatory, antioxidant, immune regulation, anti-tumor, hypoglycemic, and lipid-lowering ^[1][4].

HY-B0258

Gemfibrozil 5+ Cited Publications CI-719	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-17408

Mevastatin 5+ Cited Publications Compactin; ML236B	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic	Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-B1028

Pantethine 5 Publications Verification D-Pantethine; LBF disulfide	Endogenous Metabolite SARS-CoV	Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology Cancer
Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-N0458

Pedunculoside 3 Publications Verification	Fatty Acid Synthase (FASN)	Metabolic Disease
Pedunculoside exerts lipid-lowering effects partly through the regulation of?lipogenesis?and?fatty acid β-oxidation .

HY-W015924

2-Hydroxyisobutyric acid	Endogenous Metabolite	Metabolic Disease
2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].

HY-14668

Lomitapide mesylate 5+ Cited Publications AEGR-733 mesylate; BMS-201038 mesylate	Microsomal Triglyceride Transfer Protein (MTP) mTOR LDLR Autophagy Apoptosis	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
Lomitapide (AEGR-733; BMS-201038) mesylate is an orally active microsomal triglyceride transfer protein (MTP) inhibitor and a selective mTORC1 inhibitor with lipid-lowering activity and BBB permeability. Lomitapide mesylate significantly reduces plasma LDL levels by blocking the assembly and secretion of very-low-density lipoprotein (VLDL). Lomitapide mesylate inhibits mTORC1 in an ATP-dependent manner, thereby inducing AMPK-independent autophagic cell death and suppressing cancer cell growth and apoptosis. Lomitapide mesylate also enhances tumor infiltration of CD8 ⁺ T cells. In addition, Lomitapide mesylate inhibits HDAC, improves endothelial function, effectively alleviates vascular inflammation and oxidative stress, and exerts neuroprotective effects in a cerebral ischemia/reperfusion injury model. Lomitapide mesylate can be used in research on related diseases such as colorectal cancer, breast cancer, melanoma, ischemic stroke, and familial hypercholesterolemia .

HY-16643

Linerixibat Maximum Cited Publications 13 Publications Verification GSK2330672	Apical Sodium-Dependent Bile Acid Transporter	Infection Metabolic Disease Inflammation/Immunology
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC₅₀ of 42 nM human ASBT. Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment .

HY-W006405

Isoflavone	Estrogen Receptor/ERR	Cardiovascular Disease Cancer
Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .

HY-109523

Cerivastatin sodium 2 Publications Verification	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-14877

Anagliptin 3 Publications Verification SK-0403	Dipeptidyl Peptidase	Cardiovascular Disease Metabolic Disease
Anagliptin (SK-0403) is a highly selective, potent, orally active inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC₅₀ of 3.8 nM, and less selective at DPP-8 and DDP-9 with IC₅₀s of 68 nM and 60 nM, respectively .

HY-14925

Lapaquistat 2 Publications Verification T-91485	Endogenous Metabolite Drug Metabolite	Metabolic Disease
Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .

HY-100313A

YM-53601 5 Publications Verification	Farnesyl Transferase HCV	Infection Metabolic Disease
YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

HY-N0807

Swertiamarin 1 Publications Verification	MMP NF-κB JAK Keap1-Nrf2	Metabolic Disease Inflammation/Immunology Cancer
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating JAK2/STAT3 transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis .

HY-101701

Hepronicate Megrin	Drug Derivative	Cardiovascular Disease
Hepronicate, a nicotinic acid derivative, is a peripheral vasodilator with blood lipid lowering action. Hepronicate works by improving peripheral circulatory disturbances .

HY-N0464

D-(-)-Quinic acid 3 Publications Verification	Endogenous Metabolite Glycosidase Monoamine Oxidase	Neurological Disease Metabolic Disease
D-(-)-Quinic acid scavenges hydrogen peroxide (IC₅₀=87.11 μg/mL) and exhibits antioxidant activity. D-(-)-Quinic acid is the inhibitor for MAO and α-Glucosidase (IC₅₀ =93.75 μg/mL). D-(-)-Quinic acid is orally active .

HY-N0224

Epigoitrin 1 Publications Verification	Influenza Virus	Infection Metabolic Disease Cancer
Epigoitrin is a natural alkaloid that provides protection against influenza infection by reducing the host’s susceptibility to influenza virus under stress. Epigoitrin exerts antiviral activity against influenza A1 virus FM1 via inhibiting virus attachment and multiplication in vitro. Epigoitrin also has lipid-lowering effects .

HY-B1189

Meglutol Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .

HY-106539

Colesevelam hydrochloride	FXR G protein-coupled Bile Acid Receptor 1 GLP Receptor	Metabolic Disease Cancer
Colesevelam hydrochloride is an orally active bile acid sequestrant, lipid-lowering agent, and glycemic control agent. Colesevelam hydrochloride binds bile acids in the gastrointestinal tract to form nonabsorbable complexes, interrupts enterohepatic recirculation and increases fecal bile acid elimination. Colesevelam hydrochloride modulates FXR, TGR5, and Cyp7a1 activity and triggers cAMP signaling and GLP-1 release. Colesevelam hydrochloride alters hepatic lipid and glucose metabolism, suppresses hepatic glycogenolysis, reduces hepatic triglyceride and cholesterol levels, and increases LDL-C (low-density lipoprotein cholesterol) clearance. Colesevelam hydrochloride can be used for the research of type 2 diabetes mellitus, hypercholesterolemia, and alcohol-related liver disease .

HY-116175

BIBB 515	LDLR	Metabolic Disease
BIBB 515 is a potent, selective and orally active 2,3-oxidosqualene cyclase (OSC) inhibitor with ED₅₀ values of 0.2-0.5 mg/kg and 0.36-33.3 mg/kg in rats and mice (1-5 hours), respectively. BIBB 515 exerts lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL) .

HY-119546

Pinolenic acid PNLA	Free Fatty Acid Receptor	Inflammation/Immunology
Pinolenic acid (PNLA) is a polyunsaturated fatty acid that can be isolated from Pinus orientalis and Pinus pinaster seed oil. Pinolenic acid has anti-inflammatory and lipid-lowering activities .

HY-N9811

Hydroxytyrosol 4-O-glucoside	Drug Derivative	Infection Metabolic Disease
Hydroxytyrosol 4-O-glucoside is a phenolic compound found in olive pulp, vegetation water, and pomace of olive oil processing. Hydroxytyrosol 4-O-glucoside can be used in research on antibacterial, hypoglycemic, lipid-lowering, and cholesterol-lowering effects .

HY-109567

Gemcabene PD-72953	LDLR	Metabolic Disease Inflammation/Immunology
Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .

HY-162562

E28362	PCSK9	Metabolic Disease Inflammation/Immunology
E28362 is an orally active lipid-lowering agent and a selective PCSK9 antagonist. E28362 blocks the interaction between PCSK9 and LDLR, and induces PCSK9 degradation via the ubiquitin-proteasome pathway. E28362 significantly increases the levels of cell surface and total LDLR proteins, enhances low-density lipoprotein uptake, thereby effectively reducing plasma lipids, hepatic cholesterol and triglyceride levels. E28362 shows no obvious cytotoxicity at high concentrations, and significantly attenuates atherosclerotic lesions in animal models. E28362 is an important molecule in research of hyperlipidemia and atherosclerosis .

HY-121538

CUDA 1 Publications Verification	Epoxide Hydrolase PPAR	Cardiovascular Disease
CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-134769

OPC-163493	Mitochondrial Metabolism Reactive Oxygen Species (ROS)	Cardiovascular Disease Metabolic Disease
OPC-163493 is an orally active and liver-targeted mitochondrial uncoupling agent. OPC-163493 reduces the production of mitochondrial Δψ and ROS. OPC-163493 has anti-diabetic and lipid-lowering effects. In addition, OPC-163493 has a protective effect on cardiovascular disease .

HY-115938

BEC2	Carnitine Palmitoyltransferase (CPT) Others	Metabolic Disease Cancer
BEC2 is an ester derivative of Baicalin, with good lipid-lowering activity. BEC2 can direct activate the carnitine palmitoyltransferase 1A (CPT1A) .

HY-164853

Kanglexin	Pyroptosis NOD-like Receptor (NLR) ERK FGFR AMPK	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis .

HY-100976

LUF6283	Hydroxycarboxylic Acid Receptor (HCAR)	Metabolic Disease
LUF6283 is a potent and orally active HCA(2) partial agonist, with a K_i of 0.55 µM. LUF6283 can achieve the beneficial lipid lowering effect of niacin without producing the unwanted cutaneous flushing side effect .

HY-163436

F44-A13	FXR Cytochrome P450 RAR/RXR PPAR ROR	Metabolic Disease
F44-A13 is an orally active and highly selective farnesoid X receptor (FXR) antagonist with an IC₅₀ value of 1.1 μM. F44-A13 can optimize cholesterol metabolism and reduce its activity by inducing CYP7A1 expression. F44-A13 reduces levels of cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) in mouse models. F44-A13 can be used in the study of metabolic diseases associated with lipid disorders .

HY-P99696

Lerodalcibep LIB003	PCSK9	Cardiovascular Disease Metabolic Disease
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .

HY-113820

AZD4619	PPAR	Metabolic Disease
AZD4619 is an orally active, selective peroxisome proliferator-activated receptor α (PPARα) agonist. AZD4619 increases alanine aminotransferase 1 (ALT1) protein expression in a dose-dependent manner in human, but not in rat primary hepatocytes. AZD4619 is a lipid-lowering drug .

HY-115914

Lipid-lowering agent-1	LDLR	Others
Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .

HY-162703

Lipid-lowering agent-2	AMPK	Metabolic Disease
Lipid-lowering agent-2 (Compound 14d) is an orally active lipid-lowering agent with an EC₅₀ of 0.06 μM. Lipid-lowering agent-2 inhibits the lipid synthesis, activates the AMPK signaling pathway, and exhibits anti-obesity effect. Lipid-lowering agent-2 inhibits food intake, improves the glucose metabolism, and reduces the body weight and adipose tissue in high-fat diet (HFD)-induced obese mice .

HY-B0258S

Gemfibrozil-d6 CI-719-d₆	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-129458

Cerivastatin	HMG-CoA Reductase (HMGCR) Ferroptosis	Cardiovascular Disease Cancer
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-B0258R

Gemfibrozil (Standard) 5+ Cited Publications CI-719 (Standard)	Reference Standards PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil (Standard) is the analytical standard of Gemfibrozil. This product is intended for research and analytical applications. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-175725

NR4A1 agonist 1	Nuclear Hormone Receptor 4A/NR4A	Metabolic Disease
NR4A1 agonist 1 is a NR4A1 agonist with a K_i value of 2.96 μM. NR4A1 agonist 1 exhibits lipid-lowering activity in 3T3-L1 adipocytes, with an EC₅₀ of 0.13 μM, significantly decreasing triglyceride (TG) accumulation and lipid droplet accumulation. NR4A1 agonist 1 can be used for the study of obesity .

HY-W015924R

2-Hydroxyisobutyric acid (Standard)	Reference Standards Endogenous Metabolite	Metabolic Disease
2-Hydroxyisobutyric acid (Standard) is the analytical standard of 2-Hydroxyisobutyric acid. This product is intended for research and analytical applications. 2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].

HY-148626

CVI-LM001	PCSK9	Metabolic Disease
CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .

HY-117167

KB-141	Thyroid Hormone Receptor	Cancer
KB-141 is a potent and selective TRβ agonist. The IC₅₀ values are 23.9 nM and 3.3 nM for binding affinities from displacement of T3 from hTRα1 and hTRβ1, respectively. KB-141 has anti-obesity, anti-diabetic, and lipid-lowering effects?and can be used as an anti-cholesteremic agent in vivo .

HY-100313

YM-53601 free base	Farnesyl Transferase HCV	Metabolic Disease
YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

HY-159595

PCSK9-IN-29	LDLR PCSK9	Metabolic Disease Inflammation/Immunology
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity .

HY-W144096

Methyl 2,4,6-trihydroxybenzoate	Drug Metabolite	Metabolic Disease Cancer
Methyl 2,4,6-trihydroxybenzoate is a metabolite of 2,4,6-trihydroxybenzoate and exhibits properties as an antioxidant, lipid lowering and anticancer activities .

HY-124187

Pinolenic acid ethyl ester Ethyl pinolenate	Biochemical Assay Reagents	Others
Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.

HY-117196

GW 9578 1 Publications Verification	PPAR	Metabolic Disease Inflammation/Immunology
GW9578 is a subtype-selective PPARα agonist (EC₅₀s of 5 and 50 nM for murine and human PPAR-α) with potent lipid-lowering activity .

HY-P99773

Ongericimab JS002	PCSK9	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

HY-121538A

CUDA disodium 1 Publications Verification	Epoxide Hydrolase PPAR	Cardiovascular Disease
CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease .

Cat. No.	Product Name

HY-L253

Fungal-Sourced Compound Library

88 compounds

For thousands of years, natural products have always been an important source for drug discovery. Fungi, due to their unique and diverse secondary metabolic capabilities, have become a valuable resource for natural active molecules. Since the discovery of penicillin, natural products derived from fungi have demonstrated significant application value in areas such as anti-infection, anti-tumor, immune regulation, and metabolic disease research. A large number of clinical drugs, such as antibiotics, immunosuppressants, and lipid-lowering drugs, are derived from fungal metabolites or their structurally optimized derivatives.

MCE fungal-derived compound library contains 88 structurally diverse and bioactive fungal natural products and their derivatives. It can be widely applied in various research fields such as antibacterial, anti-tumor, anti-inflammatory, immune regulation, epigenetics, and cell signaling pathways, providing high-quality tools for natural product drug development and high-throughput screening.

Cat. No.	Product Name	Type

HY-124187

Pinolenic acid ethyl ester

Ethyl pinolenate

Biochemical Assay Reagents

Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.

Cat. No.	Product Name	Target	Research Area	Image

HY-P99696

Lerodalcibep LIB003	PCSK9	Cardiovascular Disease Metabolic Disease
Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases .

HY-P99773

Ongericimab JS002	PCSK9	Cardiovascular Disease Metabolic Disease
Ongericimab (JS002) is a humanized anti-PCSK9 monoclonal antibody. Ongericimab has lipid-lowering efficacy. Ongericimab can be used in research of hypercholesteremia and hyperlipidemia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W001171

3-Hydroxyanthranilic acid 1 Publications Verification	Human Gut Microbiota Metabolites Monophenols Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
3-Hydroxyanthranilic acid is a tryptophan metabolite in the kynurenine pathway.3-hydroxyanthranilic acid has anti-inflammatory, neuroprotective, and lipid-lowering effects. 3-hydroxyanthranilic acid can be used for researches of cardiovascular diseases, tumors, and metabolic diseases .

HY-N6653

Lentinan Maximum Cited Publications 8 Publications Verification	Polysaccharides Agaricaceae Classification of Application Fields Lentinus edodes (Berk. ) Sing Plants Disease Research Fields Saccharides Source Classification Cancer	JAK Keap1-Nrf2 Apoptosis
Lentinan is an orally active biocompatible multifunctional polysaccharide with biological activities such as anti-inflammatory, antioxidant, immune regulation, anti-tumor, hypoglycemic, and lipid-lowering ^[1][4].

HY-17408

Mevastatin 5+ Cited Publications Compactin; ML236B	Infection Cardiovascular Disease Natural Products Microorganisms Neurological Disease Classification of Application Fields Metabolic Disease Disease Research Fields Source Classification	HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G₀/G₁ phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .

HY-B1028

Pantethine 5 Publications Verification D-Pantethine; LBF disulfide	Natural Products Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite SARS-CoV
Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-N0458

Pedunculoside 3 Publications Verification	Aquifoliaceae Triterpenes Classification of Application Fields Terpenoids Parameria laevigata (Juss.) Moldenke Metabolic Disease Plants Disease Research Fields Source Classification	Fatty Acid Synthase (FASN)
Pedunculoside exerts lipid-lowering effects partly through the regulation of?lipogenesis?and?fatty acid β-oxidation .

HY-W015924

2-Hydroxyisobutyric acid	Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].

HY-W006405

Isoflavone	Flavonoids Classification of Application Fields Leguminosae Glycine max (L.) merr Other Diseases Plants Disease Research Fields Isoflavones Source Classification	Estrogen Receptor/ERR
Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .

HY-14925

Lapaquistat 2 Publications Verification T-91485	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Drug Metabolite
Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .

HY-N0807

Swertiamarin 1 Publications Verification	Monophenols other families Classification of Application Fields Phenols Zanthoxylum chiloperone var. angustifolium Metabolic Disease Plants Disease Research Fields Cancer	MMP NF-κB JAK Keap1-Nrf2
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating JAK2/STAT3 transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis .

HY-N0464

D-(-)-Quinic acid 3 Publications Verification	Infection Microorganisms other families Classification of Application Fields Ketones, Aldehydes, Acids Plants Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Glycosidase Monoamine Oxidase
D-(-)-Quinic acid scavenges hydrogen peroxide (IC₅₀=87.11 μg/mL) and exhibits antioxidant activity. D-(-)-Quinic acid is the inhibitor for MAO and α-Glucosidase (IC₅₀ =93.75 μg/mL). D-(-)-Quinic acid is orally active .

HY-N0224

Epigoitrin 1 Publications Verification	Alkaloids Classification of Application Fields Other Alkaloids Cruciferae Isatis tinctoria L. Plants Disease Research Fields Source Classification Cancer	Influenza Virus
Epigoitrin is a natural alkaloid that provides protection against influenza infection by reducing the host’s susceptibility to influenza virus under stress. Epigoitrin exerts antiviral activity against influenza A1 virus FM1 via inhibiting virus attachment and multiplication in vitro. Epigoitrin also has lipid-lowering effects .

HY-B1189

Meglutol Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid	Cardiovascular Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite
Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .

HY-119546

Pinolenic acid PNLA	Pinaceae Ketones, Aldehydes, Acids Pinus koraiensis Siebold et Zuccarini Plants Source Classification	Free Fatty Acid Receptor
Pinolenic acid (PNLA) is a polyunsaturated fatty acid that can be isolated from Pinus orientalis and Pinus pinaster seed oil. Pinolenic acid has anti-inflammatory and lipid-lowering activities .

HY-N9811

Hydroxytyrosol 4-O-glucoside	Structural Classification Natural Products Plants Source Classification	Drug Derivative
Hydroxytyrosol 4-O-glucoside is a phenolic compound found in olive pulp, vegetation water, and pomace of olive oil processing. Hydroxytyrosol 4-O-glucoside can be used in research on antibacterial, hypoglycemic, lipid-lowering, and cholesterol-lowering effects .

HY-W015924R

2-Hydroxyisobutyric acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
2-Hydroxyisobutyric acid (Standard) is the analytical standard of 2-Hydroxyisobutyric acid. This product is intended for research and analytical applications. 2-Hydroxyisobutyric acid (2-HIBA) is a selective modulator of the Insulin/IGF-1 pathway and the p38 MAPK pathway, which reduces reactive oxygen species (ROS) and fat accumulation in Caenorhabditis elegans. 2-Hydroxyisobutyric acid promotes β-oxidation and inhibits fatty acid synthesis by upregulating SKN-1/NRF2 and downregulating SREBP-1c transcription factors. 2-Hydroxyisobutyric acid has anti-aging and lipid-lowering effects, and can be used to study metabolic diseases such as obesity and diabetes. 2-Hydroxyisobutyric acid is also a renewable precursor of methacrylate through 2-HIB-CoA mutase-mediated biosynthesis[1][2].

HY-100313

YM-53601 free base	Alkaloids Carbazole Alkaloids	Farnesyl Transferase HCV
YM-53601 free base, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 free base inhibits squalene synthase derived from human hepatoma cells with an IC₅₀ of 79 nM. Lipid-lowering agent . YM-53601 free base is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .

HY-W144096

Methyl 2,4,6-trihydroxybenzoate	Classification of Application Fields Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Drug Metabolite
Methyl 2,4,6-trihydroxybenzoate is a metabolite of 2,4,6-trihydroxybenzoate and exhibits properties as an antioxidant, lipid lowering and anticancer activities .

HY-N0224R

Epigoitrin (Standard)	Alkaloids Structural Classification Other Alkaloids Cruciferae Isatis tinctoria L. Plants Source Classification	Influenza Virus Reference Standards
Epigoitrin (Standard) is the analytical standard of Epigoitrin. This product is intended for research and analytical applications. Epigoitrin is a natural alkaloid that provides protection against influenza infection by reducing the host’s susceptibility to influenza virus under stress. Epigoitrin exerts antiviral activity against influenza A1 virus FM1 via inhibiting virus attachment and multiplication in vitro. Epigoitrin also has lipid-lowering effects .

HY-B1028R

Pantethine (Standard) D-Pantethine (Standard); LBF disulfide (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite SARS-CoV
Pantethine (Standard) is the analytical standard of Pantethine. This product is intended for research and analytical applications. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-N0458R

Pedunculoside (Standard)	Aquifoliaceae Triterpenes Structural Classification Terpenoids Parameria laevigata (Juss.) Moldenke Plants Source Classification	Reference Standards Fatty Acid Synthase (FASN)
Pedunculoside (Standard) is the analytical standard of Pedunculoside. This product is intended for research and analytical applications. Pedunculoside exerts lipid-lowering effects partly through the regulation of lipogenesis and fatty acid β-oxidation .

HY-B2171AR

Carubicin hydrochloride (Standard) Carminomycin hydrochloride (Standard); Carminomicin I hydrochloride (Standard)	Quinones Microorganisms Anthraquinones Phenols Polyphenols Source Classification	Reference Standards Apoptosis
Isoflavone (Standard) is the analytical standard of Isoflavone. This product is intended for research and analytical applications. Isoflavone is an orally available bioactive component of soy phytoestrogen with lipid-lowering and antioxidant activities. Isoflavone prevents a variety of chronic diseases by regulating fatty acid oxidation in the liver and gene expression in adipose tissue. In addition, isoflavone has important value in the research of cancer and cardiovascular diseases .

HY-B1189R

Meglutol (Standard) Dicrotalic acid (Standard); 3-Hydroxy-3-methylglutaric acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	HMG-CoA Reductase (HMGCR) Autophagy Endogenous Metabolite Reference Standards
Meglutol (Standard) is the analytical standard of Meglutol. This product is intended for research and analytical applications. Meglutol is a lipid-lowering agent. Meglutol can reduces cholesterol, triglycerides, serum β-lipoprotein, and phospholipids, and inhibits the activity of HMG-CoA reductase (a rate-limiting enzyme in cholesterol biosynthesis). Meglutol can induce significant lipid oxidative damage in brain tissue. It is promising for research in the field of cardiovascular diseases and metabolic diseases .

HY-W144096R

Methyl 2,4,6-trihydroxybenzoate (Standard)	Phenols Polyphenols Endogenous metabolite Source Classification	Drug Metabolite Reference Standards
Methyl 2,4,6-trihydroxybenzoate is a metabolite of 2,4,6-trihydroxybenzoate and exhibits properties as an antioxidant, lipid lowering and anticancer activities .

HY-N7971

2-Hydroxy-1-Methoxyaporphine	Cardiovascular Disease Alkaloids Monophenols Classification of Application Fields Phenols Nelumbo nucifera Gaertn. Plants Isoquinoline Alkaloids Disease Research Fields Nymphaeaceae Source Classification	Endogenous Metabolite
2-Hydroxy-1-Methoxyaporphine is an alkaloid that can be isolated from Nelumbo nucifera. 2-Hydroxy-1-Methoxyaporphine is the major active ingredient of the Chinese traditional medicine Jiang-Zhi-Ning .

Cat. No.	Product Name	Chemical Structure

HY-B0258S

Gemfibrozil-d6
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-B1028S

Pantethine-15N2

Pantethine- ¹⁵N₂ is the ¹⁵N₂ labeled Pantethine. Pantethine is an orally active lipid-lowering agent. Pantethine has anti-tumor, anti-inflammatory and anti-SARS-COV virus activities. Pantethine is also a neuroprotective agent. Pantethine can be used in the study of Alzheimer's disease, Parkinson's disease, major depression, systemic sclerosis and pantothenate kinase-related neurodegeneration .

HY-138166S

Rosuvastatin lactone-d6

Rosuvastatin lactone-d₆ is the deuterium labeled Rosuvastatin lactone. Rosuvastatin lactone is a metabolite of Rosuvastatin (HY-17504A), a statin lipid-lowering agent and HMG-CoA inhibitor. Rosuvastatin lactone exhibits endothelium-independent and HMG-CoA reductase-independent vasorelaxant activity in rat aortic rings, and its vasorelaxant effect is jointly mediated by NO produced by inducible nitric oxide synthase (iNOS) located in vascular smooth muscle and activation of potassium channels. Rosuvastatin lactone itself has no lipid-lowering effect .

HY-109523S

Cerivastatin-d3 sodium

Cerivastatin-d₃ sodium is deuterated labeled Cerivastatin sodium (HY-109523). Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .

HY-B0258S1

Gemfibrozil-d6-1
Gemfibrozil-d6-1 (CI-719-d6-1) is the deuterium labeled Gemfibrozil (HY-B0258). Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Lipid-lowering

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products